RBC Capital upgraded Bio-Techne to Outperform and lifted its price target from $61 to $73. Bio-Techne shares are down 26% over the past year and 25% year-to-date. Get Discounted Real-Time Trade Alerts For a Volatile Market ( Labor Day Special )

A large exercise of company stock options by Robert V Baumgartner, Director at Bio-Techne TECH was disclosed in a new SEC filing on August 27, as part of an insider exercise. What Happened: A notable Form 4 filing on Wednesday with the U.S.

TECH tops Q4 EPS estimates and posts solid revenues, but shrinking margins and operating loss drag shares lower.

TECH eyes modest Q4 growth as strong reagent and instrumentation demand offsets NIH and tariff concerns.

TECH teams up with USP to boost mAb and gene therapy testing, aiming to simplify analytics and enhance product quality.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst Tom Nikic initiated coverage on Columbia Sportswear Company COLM with a Hold ...